Proxima Ventures Ltd
20
16M
15
6
0.25
1
- Stages of investment
- Areas of investment
Summary
The company was established in Asia in Israel. The leading representative office of defined VC is situated in the Tel Aviv.
The fund has specific favorite in a number of founders of portfolio startups. For fund there is no match between the location of its establishment and the land of its numerous investments - China. Among the most popular portfolio startups of the fund, we may highlight HiFiBiO, Cygnus Biosciences, Soluto. Among the most successful fund investment fields, there are Advertising, Health Care. Besides, a startup requires to be at the age of 2-3 years to receive the investment from the fund.
The common things for fund are deals in the range of 5 - 10 millions dollars. Speaking about the real fund results, this VC is 10 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2018. Despite it in 2019 the fund had an activity. The fund is constantly included in less than 2 deals per year. The higher amount of exits for fund were in 2013. Comparing to the other companies, this Proxima Ventures Ltd performs on 19 percentage points less the average number of lead investments.
The usual cause for the fund is to invest in rounds with 3-4 partakers. Despite the Proxima Ventures Ltd, startups are often financed by Founder Collective, Yueyin Venture Capital, Nest.Bio Ventures. The meaningful sponsors for the fund in investment in the same round are Yueyin Venture Capital, Giza Venture Capital, Founder Collective. In the next rounds fund is usually obtained by Giza Venture Capital, Bessemer Venture Partners, initial.vc.
The fund was created by Chaim Venezia, Uri Ra'anan, Zvi Margalit. Besides them, we counted 4 critical employees of this fund in our database.
Investor highlights
Discover reliable insights
Find relevant VC investors, identify key contacts and secure funding opportunities.
Investments analytics
Analytics
- Total investments
- 20
- Lead investments
- 6
- Exits
- 1
- Follow on index
- 0.25
- Investments by industry
- Biotechnology (9)
- Health Care (5)
- Therapeutics (5)
- Medical (3)
- Psychology (3) Show 17 more
- Investments by region
-
- United States (6)
- China (9)
- France (1)
- Israel (4)
- Peak activity year
- 2018
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 8
- Avg. valuation at time of investment
- 8M
- Group Appearance index
- 0.90
- Avg. company exit year
- 5
- Avg. multiplicator
- 7.22
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Applied Physiology | 24 Jul 2009 | Medical, Psychology, Clinical Trials | Early Stage Venture | 5M | Victoria, Australia, Australia |
| Bioelectronica | 08 Feb 2021 | Biotechnology, Health Diagnostics, Electronics | Early Stage Venture | 0 | United States, Nevada, Reno |
| Jobssy.com | 01 Jul 2011 | Artificial Intelligence, Enterprise Software, Social Media | Seed | 708K | United States, California, San Francisco |
| Rapafusyn Pharmaceuticals | 20 Jun 2024 | Early Stage Venture | 28M | United States, Maryland, Baltimore | |
| Starcounter | 01 Feb 2006 | Software, Artificial Intelligence, Enterprise Software, Database, Data Mining | Seed | 5M | Stockholm County, Stockholm, Sweden |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.